Data / Drug companies / L. Perrigo Company
L. Perrigo Company: 230 products in the FDA NDC directory, labeler code 0113
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
L. Perrigo Company (labeler code 0113) lists 230 products in the FDA National Drug Code Directory, covering 70 finished drugs by generic name. By type: 197 over the counter drugs, 33 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 15, 2026.
The request: Watch L. Perrigo Company (FDA labeler code 0113): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0113
- Products in commercial distribution
- 230
- Packages
- 418
- Finished drugs by generic name
- 70
- Prescription products
- 0
- Over the counter products
- 197
- Flagged as original packager
- 181 of 181 products that carry the flag
- Started marketing in the last 12 months
- 24
- Earliest marketing start
- July 15, 1987
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 124 | 53.9% |
| Over the counter monograph drugs | 65 | 28.3% |
| Drugs for further processing | 33 | 14.3% |
| New drug applications (NDA) | 8 | 3.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 197 | 85.7% |
| Drugs for further processing | 33 | 14.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 36 | 15.7% |
| Tablet, film coated | 35 | 15.2% |
| Suspension | 18 | 7.8% |
| Tablet | 14 | 6.1% |
| Lozenge | 14 | 6.1% |
| Gum, chewing | 11 | 4.8% |
| Tablet, chewable | 11 | 4.8% |
| Tablet, film coated, extended release | 10 | 4.3% |
| Cream | 9 | 3.9% |
| Capsule, liquid filled | 8 | 3.5% |
| Tablet, coated | 7 | 3% |
| Ointment | 6 | 2.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Good sense acid reducer | 0113-7099 | Tablet, film coated | Generic drugs (ANDA) | October 15, 2026 |
| Good sense nicotine | 0113-6305 | Lozenge | Generic drugs (ANDA) | September 17, 2026 |
| Good sense nicotine | 0113-6099 | Lozenge | Generic drugs (ANDA) | September 3, 2026 |
| Good sense daytime | 0113-7019 | Tablet, film coated | Over the counter monograph drugs | June 19, 2026 |
| Good sense daytime | 0113-5305 | Solution | Over the counter monograph drugs | May 14, 2026 |
| Good sense infants pain and fever | 0113-9523 | Suspension | Over the counter monograph drugs | May 7, 2026 |
| Good sense omeprazole | 0113-6010 | Capsule, delayed release | Generic drugs (ANDA) | May 7, 2026 |
| Good sense daytime nighttime cold and flu | 0113-5800 | Kit | Over the counter monograph drugs | May 7, 2026 |
| Option 2 | 0113-8099 | Tablet | Generic drugs (ANDA) | April 20, 2026 |
| Good sense nicotine | 0113-7969 | Lozenge | Generic drugs (ANDA) | March 5, 2026 |
| Mederma PM | 0113-4124 | Cream | Over the counter monograph drugs | March 5, 2026 |
| Good sense nicotine | 0113-7999 | Lozenge | Generic drugs (ANDA) | February 26, 2026 |
| Good sense childrens ibuprofen | 0113-6040 | Tablet, chewable | Generic drugs (ANDA) | February 26, 2026 |
| Good sense hair regrowth treatment | 0113-7080 | Aerosol, foam | Generic drugs (ANDA) | February 23, 2026 |
| Goodsense combo pack daytime and nighttime | 0113-5970 | Kit | Over the counter monograph drugs | February 20, 2026 |
| Good sense nicotine | 0113-4111 | Gum, chewing | Generic drugs (ANDA) | January 23, 2026 |
| Good sense night time | 0113-6012 | Solution | Over the counter monograph drugs | January 22, 2026 |
| Good sense combo pack daytime and nighttime | 0113-6219 | Kit | Over the counter monograph drugs | January 8, 2026 |
| Good sense nasal | 0113-6200 | Spray | Over the counter monograph drugs | January 8, 2026 |
| Good sense tussin | 0113-2009 | Solution | Over the counter monograph drugs | January 8, 2026 |
| Good sense nicotine | 0113-7031 | Lozenge | Generic drugs (ANDA) | January 2, 2026 |
| Good sense nicotine | 0113-7020 | Lozenge | Generic drugs (ANDA) | January 2, 2026 |
| Good sense nicotine | 0113-6020 | Gum, chewing | Generic drugs (ANDA) | January 2, 2026 |
| Good sense dual action complete | 0113-7050 | Tablet, chewable | Generic drugs (ANDA) | November 20, 2025 |
| Good sense hair regrowth treatment | 0113-6500 | Solution | Generic drugs (ANDA) | October 24, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.